One-year randomized study of the endometrial safety and bleeding pattern of 0.25 mg drospirenone/0.5 mg 17β-estradiol in postmenopausal women

References

• Furness S, Roberts H, Marjoribanks J, et al. Hormone therapy in postmenopausal women and risk of endometrial hyperplasia. Cochrane Database Syst Rev 2009;CD000402
   Google Scholar
• Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304–13
   PubMed Web of Science ®Google Scholar
• Lethaby A, Suckling J, Barlow D, et al. Hormone replacement therapy in postmenopausal women: endometrial hyperplasia and irregular bleeding. Cochrane Database Syst Rev 2004;CD000402
   Google Scholar
• Fuhrmann U, Krattenmacher R, Slater EP, Fritzemeier KH. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception 1996;54:243–51
   PubMed Web of Science ®Google Scholar
• Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception 2000;62: 29–38
   PubMed Web of Science ®Google Scholar
• Muhn P, Fuhrmann U, Fritzemeier KH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci 1995;761:311–35
   PubMed Web of Science ®Google Scholar
• Simoncini T, Genazzani AR. A review of the cardiovascular and breast actions of drospirenone in preclinical studies. Climacteric 2010;13:22–33
   PubMed Web of Science ®Google Scholar
• Archer DF, Thorneycroft IH, Foegh M, et al. Long-term safety of drospirenone-estradiol for hormone therapy: a randomized, double-blind, multicenter trial. Menopause 2005;12: 716–27
   PubMed Web of Science ®Google Scholar
• Lin SQ, Sun LZ, Lin JF, et al. Estradiol 1 mg and drospirenone 2 mg as hormone replacement therapy in postmenopausal Chinese women. Climacteric 2011;14:472–81
   PubMed Web of Science ®Google Scholar
• Schurmann R, Holler T, Benda N. Estradiol and drospirenone for climacteric symptoms in postmenopausal women: a double-blind, randomized, placebo-controlled study of the safety and efficacy of three dose regimens. Climacteric 2004;7:189–96
   PubMed Web of Science ®Google Scholar
• Warming L, Ravn P, Nielsen T, Christiansen C. Safety and efficacy of drospirenone used in a continuous combination with 17β-estradiol for prevention of postmenopausal osteoporosis. Climacteric 2004;7:103–11
   PubMed Web of Science ®Google Scholar
• Preston RA, White WB, Pitt B, et al. Effects of drospirenone/ 17-beta estradiol on blood pressure and potassium balance in hypertensive postmenopausal women. Am J Hypertens 2005;18: 797–804
   PubMed Web of Science ®Google Scholar
• White WB, Pitt B, Preston RA, Hanes V. Antihypertensive effects of drospirenone with 17beta-estradiol, a novel hormone treatment in postmenopausal women with stage 1 hypertension. Circulation 2005;112:1979–84
   PubMed Web of Science ®Google Scholar
• White WB, Hanes V, Chauhan V, Pitt B. Effects of a new hormone therapy, drospirenone and 17-beta-estradiol, in postmenopausal women with hypertension. Hypertension 2006;48:246–53
   PubMed Web of Science ®Google Scholar
• Gambacciani M, Rosano G, Cappagli B, et al. Clinical and metabolic effects of drospirenone–estradiol in menopausal women: a prospective study. Climacteric 2011;14:18–24
   PubMed Web of Science ®Google Scholar
• Sturdee DW, Pines A, Archer DF, et al. Updated IMS recommendations on postmenopausal hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302–20
   PubMed Web of Science ®Google Scholar
• Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab 2010;95:s1–66
   PubMed Web of Science ®Google Scholar
• The 2012 hormone therapy position statement of the North American Menopause Society. Menopause 2012;19:257–71
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women. 2005; Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003348.pdf
   Google Scholar
• Food and Drug Administration. Guidance for Industry. Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms – Recommendations for Clinical Evaluation. 2003; Available at: http://www.fda.gov/downloads/Drugs/DrugSafety/InformationbyDrugClass/UCM135338.pdf
   Google Scholar
• Gerlinger C, Gude K, Alincic-Kunz S, Schafers M. Recommendation for the collection and analysis of endometrial biopsies for hormone therapies. Climacteric 2012;15:52–8
   PubMed Web of Science ®Google Scholar
• Notelovitz M, Lenihan JP, McDermott M, et al. Initial 17beta-estradiol dose for treating vasomotor symptoms. Obstet Gynecol 2000;95:726–31
   PubMed Web of Science ®Google Scholar
• Rebar RW, Trabal J, Mortola J. Low-dose esterified estrogens (0.3 mg/day): long-term and short-term effects on menopausal symptoms and quality of life in postmenopausal women. Climacteric 2000;3:176–82
   PubMedGoogle Scholar
• Shulman LP, Harari D. Low-dose transdermal estradiol for symptomatic perimenopause. Menopause 2004;11:34–9
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Hedrick Ellenson L, Ronnett BM. Blaustein’s Pathology of the Female Genital Tract, 6th edn. New York: Springer, 2011
   Google Scholar
• Hunter MS. The Women’s Health Questionnaire: a measure of mid-aged women’s perceptions of their emotional and physical health. Psychol Health 1992;7:45–54
   Web of Science ®Google Scholar
• Guy W. Clinical Global Impression. In Rush AJ, Pincus HA, First MB, eds. Handbook of Psychiatric Measures. Washington DC: APA, 2000:218–22
   Google Scholar
• Archer DF. Drospirenone and estradiol: a new option for the postmenopausal woman. Climacteric 2007;10(Suppl 1):3–10
   PubMedGoogle Scholar